Breast cancer survivor offers wisdom at Faulkner satellite center
Call 877-422-3324 today to make an appointment
Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.
Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.
Toll-Free Number866-408-DFCI (3324)
Discover the ways to give and how to get involved to support Dana-Farber.
Poet Richard Fox gains insight – and material – through cancer treatment
A family faces cancer in an unfamiliar city – with help
Choosing mastectomy or not: Studying young women's surgical choices
Jeff's targeted therapy has kept his advanced lung cancer at bay.
Dana-Farber Cancer Institute maintains a variety of resources to support the research and educational activities of Dana-Farber faculty. These core facilities, shared resources, and integrative research centers offer research services to the Boston research community, including academic institutions and industry.
Biocontainment Core Facility (BL2+)
Biospecimen Repository Core
Clinical Research Laboratory
Confocal and Light Microscopy Core
Connell and O'Reilly Families Cell Manipulation Core
Experimental Therapeutics Core
Flow Cytometry Core
Health Communication Core
Leukemia/Lymphoma Xenograft (LLX) Core
Microarray Core Facility
Molecular Biology Core Facilities
Molecular Diagnostics Laboratory
Monoclonal Antibody Core
Nuclear Magnetic Resonance Core
RNA Interference (RNAi) Screening Facility
Structural Biology Facility
Tumor Imaging Metrics Core
Survey and Data Management Core
Integrative Research Centers
The Dana-Farber Biocontainment Core Facility supports researchers whose experiments require a Biosafety Level 2+ (BL2+) containment level. The Biocontainment core adheres to Biosafety Level 3 (BL3) practices. Protective apparel, equipment, and other materials are provided by the core. Two core facilities are available: one is located at the Jimmy Fund building at Dana Farber; the second at The Center for Life Science. Authorized core users may have access to both facilities.
Use of the facility is limited to researchers who receive training in BL3 procedures and comply with authorized user requirements. Training is provided by the Biosafety Officer, Core Manager, and authorized users.
Jimmy Fund 7 (JFB715-725) and Center for Life Science (CLS 1019B)
Core Manager: Denise Pearson Email: email@example.comPhone: 617-632-3377
The Biospecimen Repository provides long-term storage of clinical and research material in -80º C and liquid nitrogen freezers. Transportation of samples to and from the repository is provided for an additional fee. Competitive prices are available on a per box or per freezer basis in either segregated or non-segregated environments.
The core provides affordable monthly fees inclusive of operation and maintenance, and costs that are proportional to your storage needs.
Manager: Evangeline Reynolds Phone: 617-582-7441Website: biospecimenrepositorycore.dana-farber.org
Biostatistics provides expertise for the planning, conduct, analysis, and reporting of clinical trials, epidemiologic and population based studies, studies in genetic susceptibility of cancer, and experiments in basic research in the biology of cancer. Services also include: advice and consultation in efficient and accurate database design and management of clinical research data; scientific computing for data analysis and scientific graphics; and education in the areas of study design, data collection, computerization, and statistical methods for laboratory, clinical, and population based studies.
Director: Paul Catalano, ScDCo-Director: Rebecca Gelman, PhDPhone: 617-632-3014Website: www.dfhcc.harvard.edu/core-facilities/biostatistics/
The Clinical Research Laboratory (CRL) utilizes protocol-driven standard operating procedures for the processing of pharmacokinetics, pharmacodynamic, and biomarker samples. This includes the processing, storage, and tracking of all research specimens to ensure the successful completion of clinical trials associated with patient treatment. The CRL is dedicated to the highest standards of specimen handling to maintain the integrity of data procurement and analysis for clinical trials.
Manager: Sujata ShahPhone: 617-632-6981
The Confocal and Light Microscopy Core provides state-of-the-art imaging microscopy technology for fixed and live cells and tissues, along with scientific and technical expertise to assist in experimental design and optimal image collection. Imaging techniques available through the core are standard fluorescence, live-cell long term imaging, confocal, TIRF, FRET, and spectral imaging. Available equipment includes a spinning disk confocal microscope, a Leica SP5 laser scanning confocal with a white light laser, and an inverted widefield fluorescence microscope. Training on all equipment, consultation about various imaging techniques, and assistance with image analysis is also available. Core staff are also able to assist with troubleshooting microscope issues in individual research labs.
Director: Lisa Cameron, PhDPhone: 617-582-8824Website: microscopy.dfci.harvard.edu
The Connell and O’Reilly Families Cell Manipulation Core Facility assists researchers in developing new cell-based therapies for cancer. All cell manufacturing procedures are performed in environmentally controlled conditions according to current Good Manufacturing Practices for cell and tissue processing. Services include the processing of hematopoietic stem cells for autologous or allogeneic transplantation, generation of tumor vaccines using genetic or culture mediated modification of tumor cells, and preparation of immune cell populations for adoptive cellular therapy.
Cell processing for patients enrolled in clinical research protocols, including:
Since most cell manipulation procedures are distinct and developmental, the cost of each procedure is determined individually for each protocol. Charges to principal investigators are based on the laboratory costs determined for each protocol.
Director: Jerome Ritz, MDAssistant Medical Director: Sarah Nikiforow, MD, PhD Phone: 617-632-2251Website: www.dfhcc.harvard.edu/core-facilities/cell-manipulation/
The Experimental Therapeutics (ETx) Core is a preclinical resource to Dana-Farber Cancer Institute (DFCI) researchers and collaborators for conducting in vivo pharmacological studies. Studies will be run at a 14,000-square-foot preclinical facility shared with the Lurie Family Imaging Center (LFIC) that features bioluminescent imaging using the IVIS Spectrum system.
Our mission is to help DFCI investigators by providing high quality in vivo pharmacology studies that enable DFCI investigators’ translational research and chemistry and drug discovery/development efforts. These include studies that determine efficacy of new therapies and new combinations, advance preclinical studies to initiate clinical trials, and target identification and validation.
The Experimental Therapeutics Core will provide expertise for in vivo pharmacology studies, including drug tolerability and efficacy studies; pharmacodynamic and mechanism-of-action studies, and tumor model development. Our capabilities include both subcutaneous and orthotopic tumor implantations and animal dosing by all common routes of administration, e.g. intraperitoneal, intravenous, oral and subcutaneous, and in combination. Comprehensive tumor and tissue harvesting is available for every study. Fresh samples can be sent to investigators or preserved by formalin fixation and/or flash freezing.
Director: Praful Gokhale, PhDEmail: Prafulla_Gokhale@dfci.harvard.eduPhone: 617-632-6919
The Flow Cytometry Core Facility provides sterile sorting and analysis of samples in support of research at DFCI. The core has 2 high-speed cell sorters, the BD FACSAria II SORP (5laser) and BD FACSAria IIu (3 laser) with up to 17-color detection utilizing multi-laser platforms. Sample populations can be sterile sorted into a variety of tubes or plates. The BD FACSAria II SORP and BD FACSAria IIu are both equipped with the Automated Cell Deposition Unit (ACDU) for sterile single cell sorting into 96, 384 micro titer plates as well as PCR plates.
AnalysisThe core presently has 2 analyzers, the BD LSRFortessa SORP (4laser) and BD LSRII (3laser) with up to 12-color simultaneous detection utilizing multi-laser platforms. The BD LSR II is also equipped with an HTS(high throughput sampler) for analyzing samples directly from 96 well micro titer plates as well as being able to run 5ml tubes.
ServicesThe Facility staff is available to assist researchers with their sorting and analysis needs. Researchers who would like to utilize the analyzers are trained so that they can analyze their experiments independently. The staff will assist with data acquisition and analysis as well as interpretation. They will also assist in experiment design and implementation as well as troubleshooting. Training sessions are available for researchers.
Senior Director: John DaleyEmail: firstname.lastname@example.orgPhone: 617-632-3179Website: flowlab.dfci.harvard.edu
The Health Communication Core provides professional creative services to researchers and clinicians from Dana-Farber/Harvard Cancer Center, Dana-Farber Cancer Institute, and other medical and research institutions. The core provides everything from writing, editing, and graphic design to web site development, high-end print production, and audience research. Evidence-based practices with creative expertise are combined to develop materials and communication strategies that help researchers successfully reach their audience.
The core provides creative expertise in the areas of:
Director: Vish Viswanath, PhDAssistant Director: Catherine ColemanPhone: 617-632-5078Email: email@example.comWebsite: www.healthcommcore.org
Patient-derived xenografts (PDXs), generated by transplanting primary human tumor cells into immune-deficient NSG mice, surmount some of the limitations of traditional in vivo platforms and have been increasingly utilized as tools for preclinical investigation. We have established a repository of PDX models of leukemia and lymphoma, which we have named the Public Repository of Xenografts (PRoXe). The repository encompasses AML, B- and T-ALL, and B- and T-cell non-Hodgkin lymphoma across a range of cytogenetic- and molecularly-defined subtypes. PRoXe is extensively annotated with patient-level information, including demographics, phase of treatment, prior therapies, tumor immunophenotype, cytogenetics, and molecular diagnostics. PDX lines available for distribution are characterized by immunophenotyping, whole transcriptome sequencing (RNAseq), and targeted exon sequencing of ~300 genes.
The Leukemia/Lymphoma Xenograft Core was established to expand our xenografting efforts and to expedite sample allocation to interested investigators. To browse our PDX models and request lines for use in research, please visit the PRoXe website.
The Core provides expertise in the areas of:
Director: Amanda ChristiePhone: 617-582-8868Email: AmandaL_Christie@dfci.harvard.edu
Faculty Sponsor: David Weinstock, MDPhone: 617-632-4245Email: DavidM_Weinstock@dfci.harvard.edu
Browse and request models on PRoXe WebsiteRegister for our Core at the LLX Core Website
The Medical Arts Core offers complete services for publications, presentations and advertising including:
Photoshop via Medical Arts WebEx is the way to go. Please call us for more information. When using DFCI Medical Arts Core, your Data Files will always be highly secured and strictly confidential.
Director: Minou ModabberPhone: 617-632-3198Website: medicalartscore.dana-farber.org
The Medicinal Chemistry Core collaborates with researchers to accelerate the development of novel therapeutic agents. The Core is comprised of experienced medicinal and synthetic chemists with lab space located in Dana-Farber's Harbor Campus. The labs are fully equipped to perform synthetic organic chemistry on a small to multi-gram scale, with LCMS, reverse phase chromatography, and access to the NMR facilities at Dana-Farber and Harvard Medical School.
Director: Nathanael Gray, PhDLead Scientist: David Scott, PhDPhone: 617-582-7256Website: medicinalchemistrycore.dana-farber.org
The Microarray Core Facility offers Gene Expression Profiling, SNP, miRNA, and CNV analysis using array technologies from Affymetrix. The Microarray Core specializes in processing RNA extracted from Formalin-Fixed Parafin embedded tissue. The core is well integrated into the Genomics core which provides additional next generation sequencing services. In this way your project lands up on the right platform.
Director: Paul MorrisonPhone: 617-632-3082Website: mbcf.dfci.harvard.edu
The Molecular Diagnostics Laboratory provides microRNA expression profiling, human cell line identity verification, mutation detection for clinical research studies, and specimen processing for clinical research studies. Consultation on experimental design and assistance with data analysis is also available.
Director: Sigitas Verselis, PhDEmail: Sigitas_Verselis@dfci.harvard.eduPhone: 617-632-2115Website: moleculardiagnosticscore.dana-farber.org
The Molecular Biology Core Facilities offer a full suite of molecular biology services, including automated DNA sequencing, genotyping, peptide synthesis, protein sequencing, amino acid analysis, BIA core protein ligand assays, and mass spectrometry. DNA sequencing and genotyping services include synthesis and tracking of oligonucleotides, contig building, and publication to appropriate databases. Various mass spectrometry services are also available, including LTQ Orbitrap and 4800 TOF/TOF.
The Monoclonal Antibody Core produces novel monoclonal antibodies for use in basic research, drug discovery, and clinical applications including diagnosis, surrogate markers for disease status, response to therapy, and drug toxicity. Services include cloning and scale-up of immunization antigens to purification of the resulting antibodies. Researchers can choose to have all phases of antibody production conducted by the core or perform particular steps in their own lab.
Core Director: Ed Greenfield, PhDPhone: 617-632-2209Scientific Advisor: James Decaprio, MDPhone: 617-632-6266Website: mabcore.dfci.harvard.edu
The Nuclear Magnetic Resonance (NMR) Core, jointly
operated by Harvard Medical School and Dana-Farber, provides expert support and
instrumentation for a broad range of chemical, biochemical, and structural
biology research problems. We work with collaborators to design and implement
time-efficient and cost-effective NMR approaches to chemical problem solving,
biochemical interaction studies, ligand and fragment screening, ligand-target
binding studies, metabolomics, and macromolecular structure determination. We
are available to provide technical and scientific training in NMR methods as
well as hands-on instrument training.
Dana-Farber Lab Manager: Walter Massefski, PhDPhone: 617-632-1987Website: http://eqnmr.med.harvard.eduLocation: Longwood Center, 3rd floor, Room 3301
The RNAi Screening Facility provides investigators with access to RNAi reagents and high-throughput screening technology. Lentiviral-based RNAi constructs against the human and mouse genomes are provided by the RNAi Consortium of the Broad Institute, and can be used to transduce a wide range of target cells, including primary and non-dividing cells. The Facility provides reagents, equipment, and technical expertise to design, optimize, and perform cell-based, arrayed lentiviral RNAi screens. Additionally, lentiviral RNAi constructs against individual genes can be requested.
Director: William Hahn, MD, PhDCo-Director: Anna Schinzel, PhDPhone: 617-582-7649
Through collaborations with Dana-Farber and Longwood-area laboratories, the Structural Biology Facility helps solve chemical and structural biology problems in the field of cancer research. The team performs and contributes to mechanism of action studies and structural biology by generating high quality proteins and executing biophysical characterization experiments, binding kinetic and thermodynamic analysis, assay development, and fragment-based or compound library screening. Notably, the team conducts X-ray crystallography for use in a wide variety of studies, including structure-guided drug discovery.
Director: Sirano Dhe-Paganon, PhDEmail: firstname.lastname@example.orgPhone: 617-632-3530Website: structuralbiologyfacility.dana-farber.org
The Tumor Imaging Metrics Core (TIMC) provides standardized, consistent, longitudinal radiological measurements to evaluate therapeutic response for DF/HCC clinical trials. Services include accurate, consistent, and timely analysis of CT, MR, and PET/CT imaging studies. Measurements available include linear (RECIST, WHO, Cheson), volumetric measures for CT or MR scans, and Standardized Uptake Value (SUV) for PET scans. Results of analyses are offered on a password-protected secure web-based report. This core also provides an independent service with verifiable measurement of treatment response for patients enrolled in trials, and serves as a centralized, computerized resource to facilitate efficient internal or external auditing.
Reliable tracking of changes in lesion size or function is essential for clinical trials that use radiological measurements as surrogate endpoints. The Tumor Metrics Core provides a service for managing these images, making measurements in a routine, reliable, and centralized way, and making results available to investigators efficiently.
The Tumor Metrics Core provides four primary services to DF/HCC investigators:
The Tumor Imaging Metrics Core will maintain a database of longitudinal radiological and clinical data that will link to the Quality Assurance for Clinical Trials (QACT) Core to provide an auditable record of quantitative measurements for clinical trials conducted through the DF/HCC.
Director: Gordon Harris, PhDDirector: Annick Van den Abbeele, MDPhone: 617-632-2595Website: www.tumormetrics.org
The Survey and Data Management Core provides efficient, high-quality data collection, management services, and consultation. The core provides expertise and technical support in the areas of development and implementation of data collection protocols from study participants, quality control of data collection processes, and data management. Capabilities include the development and implementation of survey research projects, the development of complex databases, project evaluation, cognitive interviewing, focus groups, in-depth interviews, and other similar processes.
Director: Wendy London, PhD Assistant Director: Carol Lowenstein, MBAPhone: 617-582-9063Website: surveycore.org
The Translab is dedicated to supporting clinical research and offers a comprehensive battery of services, leveraging multiple technologies and methods, and can assist with routine processes as well as complex laboratory-developed tests. The Translab places a special emphasis on assay development for use in clinical trials.
Center for Life Science (CLS 3068)
Core Director: Myriam ArmantEmail: Translab@childrens.harvard.edu or Myriam.Armant@childrens.harvard.eduPhone: 617-713-8085Website: www.translabboston.org
The facility provides services and resources for investigators looking to accomplish animal research objectives. This includes housing mice and rats, purchasing animals, training researchers regarding proper animal care and use, and monitoring the safety of all personnel with laboratory animal contact in conjunction with Dana-Farber’s Environmental Health and Safety and Occupational Health Services.
Dana-Farber has established an Institutional Care and Use Committee (IACUC) to oversee the Institute’s animal program, facilities, and projects involving the use of animals. The IACUC serves as the approval body for all protocols involving animal research, and assists faculty, students and staff in upholding Dana-Farber’s commitment to providing the finest care and most humane utilization of laboratory animals.
In addition to basic husbandry services, the Vivarium staff provides technical and veterinary services, mouse breeding management and mouse irradiation.
Director: Barbara Smith, DVM, PhD Associate Director: Heather Manning, MBAPhone: 617-632-6200Website: research.dfci.harvard.edu/arfsite/
Search by last name:
Browse directory of
Browse clinical trials